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Introduction
After a protracted history, neurofeedback has begun to attract
the attention and scrutiny of the scientific and medical main-
stream (Kamiya, 2011; Linden, 2014; Sitaram et al., 2017). A
debate now centres on the extent to which neurofeedback
alters brain function and behaviour, and the mechanisms
through which neurofeedback operates (e.g. neurofeedback-
specific versus non-specific). A series of correspondences in
Lancet Psychiatry (Micoulaud-Franchi and Fovet, 2016;
Thibault and Raz, 2016a, b; Pigott et al., 2017; Scho¨nenberg
et al., 2017a, b) and Brain (Fovet et al., 2017; Schabus, 2017,
2018; Schabus et al., 2017; Thibault et al., 2017, 2018; Witte
et al., 2018) discuss the theoretical arguments and empirical
data backing the involvement of these two mechanisms.
The apparent controversy that the correspondence letters
present stems from a well-known phenomenon in neuro-
psychology: that multiple components can drive the benefits
of a treatment (Enriquez-Geppert et al., 2013; Campbell and
Stanley, 2015). We depict this hypothesized multi-compo-
nent model for the context of neurofeedback in Fig. 1. We
divide the mechanisms driving experimental outcomes into
five bins: neurofeedback-specific (related to training a target
neurophysiological variable), neurofeedback non-specific (de-
pendent on the neurofeedback context, but independent
from the act of controlling a particular brain signal), general
non-specific (including the common benefits of cognitive
training as well as psychosocial influences, such as placebo
responding), repetition related (e.g. test–retest improvement),
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and natural (e.g. spontaneous remission, cognitive develop-
ment) (Micoulaud-Franchi and Fovet, 2018).
Although a framework based on these terms and con-
cepts is only beginning to concretize in the neurofeedback
literature, most scientists involved in neurofeedback agree
on their general usage and interpretation. The greater
points of contention centre on (i) whether previous experi-
ments provide sufficient evidence to identify specific factors
as a key driver of neurofeedback outcomes; and (ii) how to
best design an experiment to clearly dissociate the various
mechanisms driving neurofeedback outcomes. If neurofeed-
back outcomes occur independently of the information
provided by the neural feedback signal (i.e. come from
non-specific mechanisms), then neurofeedback does not
rely on the main criteria that set it apart from other inter-
ventions, such as cognitive training and meditation. An
ideal demonstration of neurofeedback-specific effects
would include evidence of online (i.e. intra-session) and
offline (i.e. inter-session or post-treatment) changes in tar-
geted brain activity, as well as a control group or condition
to rule out non-specific effects (e.g. sensory stimulation,
placebo). Individual neurofeedback studies, however, con-
tain varying proportions of each of these criteria and have
led to a diversity of opinions regarding the specificity of
mechanisms involved in neurofeedback. The present check-
list provides the structure to develop a more comprehensive
and rigorous evidence base.
Evidence for putatively causal, neurofeedback-specific
mechanisms relies on our knowledge of the physiological
basis of neural activity and its relevance to cognition (for a
review of neurofeedback mechanisms, see Ros et al., 2014;
Sitaram et al., 2017). For example, the association between
neural activity and cognition in animals (Cao et al., 2016;
Babapoor-Farrokhran et al., 2017) suggests that self-regu-
lation of brain circuits can alter behaviour and cognition. A
number of neurofeedback experiments in animals (Sterman
et al., 1970; Schafer and Moore, 2011), and humans
(Watanabe et al., 2017; Young et al., 2017b) further sup-
port this view. Evidence suggesting that mechanisms other
than neurofeedback-specific factors account for the effects
of neurofeedback come from a number of recent studies
and reviews that find comparable benefits between partici-
pants who receive veritable neurofeedback from their own
brain and those who observe a sham-neurofeedback signal
unrelated to their neural activity of interest (Schabus et al.,
2017; Scho¨nenberg et al., 2017a; Thibault and Raz, 2017).
To advance the field of neurofeedback, scientists can
benefit from designing future studies with the methodo-
logical rigour capable of disentangling the various mechan-
isms driving the effects of neurofeedback. As authors of the
correspondence, alongside other researchers active in the
field, we propose a standardized checklist outlining best
practices in the experimental design and reporting of neu-
rofeedback studies. We believe that widespread adoption of
this checklist will help advance our scientific understanding
of how neurofeedback affects brain function and
behaviour.
Objectives of the checklist
This checklist is intended to encourage robust experimental
design and clear reporting for clinical and cognitive-behav-
ioural neurofeedback experiments (for a methodological
review see Ros et al., 2014; Enriquez-Geppert et al.,
2017). Because all neurofeedback aims to train brain activ-
ity, these guidelines generalize across EEG, magnetoencepha-
lography (MEG), functional MRI, functional near infrared
spectroscopy (fNIRS), and other neurofeedback modalities.
The checklist focuses mainly on aspects unique to the neu-
rofeedback context (as general standards for each imaging
modality already exist; Gross et al., 2013; Nichols et al.,
2017; Pernet et al., 2018). It serves as a complement,
rather than alternative, to the Consolidated Standards of
Reporting Trials (CONSORT) guidelines (Schulz et al.,
2010) (http://www.consort-statement.org/checklists). When
submitting neurofeedback results for publication, we encou-
rage researchers to include the checklist (Fig. 2), ideally
using the application available at www.rtfin.org/CREDnf.
Alternatively, the checklist can be downloaded from the
Supplementary material and the final column can be filled
with the relevant text from your manuscript, or the page
number identifying where in the manuscript each item is
addressed. This checklist does not aim to inhibit the explor-
ation of novel directions in neurofeedback research. On the
contrary, it advocates robust designs and clear reporting to
promote informed research decisions that can effectively
build upon previous work. These guidelines are a first iter-
ation. As neurofeedback research progresses, we invite the
community to provide comments for improving this check-
list (see rtfin.org/CREDnf for a link to the commenting plat-
form). We hope these guidelines will help disentangle the
relative contribution of the mechanisms outlined in Fig. 1.
Description of checklist
items
Below, we include a short description of each checklist item
followed by examples from published neurofeedback
articles.
Pre-experiment
Item 1a. Preregister experimental protocol and
planned analyses
This item is essential for clinical and replication studies,
and is encouraged for others.
Preregister, for example, on a platform such as www.o
sf.io, as a randomized controlled trial (RCT) on
ClinicalTrials.gov or the European Union Clinical Trials
Register (EUCTR), or by submitting a registered report
(see www.cos.io/rr for information concerning registered
reports). Clearly label primary and secondary outcome
variables. Indicate the number, frequency, and duration
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of neurofeedback sessions. In the publication, report
which analyses were preregistered, which were explora-
tory, and disclose any potential deviations from the pre-
registered protocol.
Examples:
(i) See The Collaborative Neurofeedback Group (2013) for a
pre-published protocol of a double-blind multisite RCT, and
https://clinicaltrials.gov/ct2/show/NCT02251743 for the pre-
registration document.
(ii) See Holtmann et al. (2014) for a pre-published protocol of
the study by Strehl et al. (2017) with trial registry number
ISRCTN 76187185.
Item 1b. Justify sample size
This item is essential.
Describe the sampling plan and how it was determined.
Ideally, justify the sample size with a power analysis based
on the smallest effect size of interest [e.g. minimal clinically
important differences (MCIDs), see Item 6a] or another
method (e.g. Bayesian sequential sampling). Otherwise,
label the experiment as a pilot, proof-of-concept, or feasi-
bility study. If the preregistered sample size is not met, state
so. Whereas smallest effect sizes of interest may be derived
from previous literature, we do not recommend selecting a
sample size based solely on an ‘expected’ effect size derived
from previous published results. Because of publication
bias, which remains common across research fields, this
practice can leave experiments underpowered (Albers and
Lakens, 2018; Algermissen and Mehler, 2018).
Examples:
(i) ‘Estimates of a clinically relevant effect size were derived
from the Go¨ttingen pilot-study using the same primary out-
come measures [18]. It is expected that in the neurofeedback
group the mean FBB-ADHS score at Post-Test 2 is 1.20 and
in the control group 1.50 with a common standard devi-
ation of 0.55. The expected outcome requires a sample
size of 72 subjects per group (a = 0.05, two sample t-test,
two-sided) to achieve a power of 90%.’ (Holtmann et al.,
2014).
(ii) ‘Owing to feasibility and proof of principle, we intend fol-
lowing a Bayesian sampling strategy with a minimum of
N=5 patients and continue recruiting either until the Bayes
factor for both hypotheses (A and B) is conclusive - i.e.
either for the alternative with BF10 4 10 (indicating
strong evidence for a positive effect) or for the null with
BF01 4 10 (indicating strong evidence for a null effect) -
or until the end of the data collection period (September 30,
2017) is reached.’ (Mehler et al., 2017).
Control groups
Item 2a. Employ control group(s) or control
condition(s)
This item is essential.
Use a control group (between subjects) or control condi-
tion (within subjects). This could include a placebo-control
(e.g. sham-neurofeedback, neurofeedback from a largely
unrelated brain signal, or inversing the neurofeedback
reward contingency) or another active non-neurofeedback
control (e.g. a similar type of computerized cognitive train-
ing, biofeedback, or medication). See Sorger et al. (2019)
for an in-depth review of control groups in neurofeedback
research. Consider the potential for, and report any adverse
effects in both the experimental and control groups.
Examples:
(i) ‘Four separate healthy subject control groups were trained
and tested using similar or identical procedures but in the
absence of valid rACC rtfMRI information . . . Group III (n
= 8) received identical training to the experimental group,
but using rtfMRI information derived from a different brain
region in posterior cingulate cortex that is not believed to be
involved in pain processing to examine spatial and physio-
logical specificity. Group IV (n = 4) received identical train-
ing to the experimental group, but, unknown to the subjects,
the rtfMRI displays that they viewed corresponded to acti-
vation from a previously tested experimental subject’s rACC,
Figure 1 Multiple mechanisms drive the effects of neuro-
feedback training. Neurofeedback participants may benefit from:
(i) the specific neurophysiological process of training a particular
brain signal (green). Non-specific factors, including (ii) those unique
to the neurofeedback environment (e.g. trainer-participant inter-
action in a neurotechnology context) (dark blue); and (iii) those that
are common across interventions (e.g. all other benefits from
engaging in a form of cognitive training as well as the psychosocial
and placebo mechanisms related to participating in an experiment)
(light blue). (iv) Repetition-related effects (purple). (v) Natural ef-
fects, which can be positive (e.g. cognitive development in child-
hood) or negative (e.g. cognitive decline in older age) (orange).
These mechanisms may interact synergistically to create a greater
overall effect, interact antagonistically to lessen the total benefit, or
combine additively (for a discussion of this topic, see Rothman,
1974; Finnerup et al., 2010). By including control groups, carefully
designing experiments, and measuring both brain activity and be-
haviour, researchers can better estimate the contribution from each
of these mechanisms.
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rather than their own rACC brain activation.’ (deCharms
et al., 2005).
(ii) ‘As a semi-active control condition EMG feedback of coord-
ination in the supraspinatus muscles was chosen.
Participants were instructed either to contract or to relax
the left relative to the right supraspinatus muscle. This
protocol was chosen to induce differential EMG control cor-
responding to the “polarities” comparable to the NF condi-
tion, without requiring simple relaxation or tension. This
allowed us to use the same device and the same representa-
tion of the feedback signal on the screen. We did not choose
a standard EMG feedback protocol because the control con-
dition should be as unspecific as possible but include the
possibility to learn self-regulation, i.e. the unspecific variable
of any biofeedback treatment.’ (Strehl et al., 2017).
Item 2b. When leveraging experimental designs
where a double-blind is possible, use a double-blind
This item is essential.
For example, in experiments with a placebo-neurofeed-
back control group or within participant control
conditions.
Example:
‘To blind staff to treatment condition, The SmartBox interface de-
vices were independently preprogrammed by an off-site consultant
who had no interaction with participants or data (analogous to
prepackaged randomized medication).’ (Arnold et al., 2013).
Comment: Currently, few neurofeedback software packages
are designed for blinding the treatment staff.
Item 2c. Blind those who rate the outcomes, and
when possible, the statisticians involved
For this item, see Dutilh et al. (2019); this item is
encouraged.
Indicate which individuals were blinded and how blind-
ing was achieved.
Example:
‘The Behavioral Observation of Students in Schools [BOSS] . . .
is a systematic interval recording observation system for coding
classroom behavior and reports on engagement . . . and off-task
behaviors . . . Data output from observations are objective quan-
titative assessments, which can help reduce observer bias . . . The
BOSS was completed . . . for all study participants by trained RA
[research assistants] who were unaware of the participants’ ran-
domization conditions. The participants were unaware that they
were being observed.’ (Steiner et al., 2014).
Item 2d. Examine to what extent participants and
experimenters remain blinded
This item is encouraged.
For an overview on reporting whether blinding was suc-
cessful, see Kolahi et al. (2009).
Example:
‘The CSQ [consumer satisfaction questionnaire], administered at
Treatments 24 and 40, also included questions to examine
blindness to treatment assignment . . . Of 34 participants at
Treatment 40, 35% of children and 29% of parents said that
they did not know which treatment they had been assigned to
and declined to guess. Only 32% of children and 24% of par-
ents guessed correctly, with 32% and 47%, respectively, gues-
sing incorrectly.’ (Arnold et al., 2013).
Item 2e. In clinical efficacy studies, employ a
standard-of-care intervention group as a benchmark
for improvement
This item is encouraged.
This design helps establish whether neurofeedback is su-
perior to, or at least non-inferior to, standard treatments.
Example:
‘Potential participants are screened for eligibility, and those who
are eligible are randomly assigned to the treatment group
(receiving rtfMRI NFT in addition to treatment as usual) or
the control group (receiving only treatment as usual).’ (Cox
et al., 2016).
Control measures
Item 3a. Collect data on psychosocial factors
This item is encouraged.
For example, participant motivation, treatment expect-
ation, effort exerted, and subjective sense of success.
Examples:
(i) ‘To compare the NFT and the pseudo NFT group concern-
ing the plausibility of the intervention, a subject self-report
was utilized. Subjects reported on motivation to participate
in the study, commitment to the study (before each session),
and difficulty of the session (right after each session) using a
seven-point Likert-scale (1 = not at all to 7 = very strong).’
(Enriquez-Geppert et al., 2014).
(ii) ‘In the present study, the effects of sex of participant, sex of
experimenter, as well as the role of locus of control in deal-
ing with technology will be investigated . . . Although the
purpose of the present study is not to investigate further
the effects of mindfulness and SMR baseline power on neu-
rofeedback training outcomes, their impact will be measured
and controlled statistically in the experimental design.’
(Wood and Kober, 2018).
Item 3b. Report whether participants were provided
with a strategy
This item is essential.
If strategies were provided, report the details of the
strategies.
Examples:
(i) ‘Importantly, the experimenter did not provide any explicit
instruction to the participant regarding strategies; rather par-
ticipants were told to increase the number of counts and bell
rings by any mental means they could.’ (Davelaar et al.,
2018).
(ii) ‘Subjects were instructed to execute or imagine the kines-
thetic experience of a sequential finger tapping task (index-
middle-ring-little-index-middle-ring-little) from the first
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person perspective with either the right or left hand (20
trials per hand in randomized order).’ (Zich et al., 2015).
Comment: Currently there is no standard regarding the
provision of strategies, nor is there systematic research on
which strategies are the most effective (see section ‘provi-
sion of strategies’ from Enriquez-Geppert et al., 2017).
Motor-imagery-assisted brain-computer interface (BCI) is
the exception.
Item 3c. Report the strategies participants used
This item is encouraged.
Examples:
(i) ‘The reported mental strategies and the subsequent categor-
ization process are described in Table A1 of the Appendix in
more detail.’ (Kober et al., 2013)
(ii) ‘Among them, the most efficient strategies were friends
(1.625), love (1.4) and family (1.1) while the worst were
anger (–2.0) and calculation (–0.15). The effects of some
positive strategy subtypes like love (lover (1.67)), nature
(hometown (1.5)) and family (brothers (2.0)) stood out.’
(Nan et al., 2012).
Item 3d. Report methods used for online data pro-
cessing and artefact correction
This item is essential.
For example, detection and rejection/correction of ocular
and muscular artefacts (EEG, MEG), and of cardio-respira-
tory and movement artefacts (functional MRI).
Examples:
(i) ‘Before the start-baseline measurement, an EOG calibration
method (3 min) was implemented that calculates the subject-
specific, artifact-associated frequency band. This was used
for all following measurements for eye blink detection and
rejection during further measurements (for details see Huster
et al., 2014) . . . Thus, the subject-specific artifact-associated
frequency band that was calculated in the EOG calibration
measure was monitored. Whenever the mean amplitudes of
a 2 s segment was higher than the subject-specific artifact-
associated frequency band (minus one standard deviation),
the segment was rejected and not used for feedback.’
(Enriquez-Geppert et al., 2014).
(ii) ‘Pre-processing of single-subject fMRI data included correc-
tion of cardiorespiratory artifacts using AFNI implementa-
tion of the RETROICOR method. The cardiac and
respiratory waveforms recorded simultaneously during each
fMRI run were used to generate the cardiac and respiratory
phase time series for the RETROICOR.’ (Young et al.,
2014).
Item 3e. Report condition and group effects for
artefacts
This item is encouraged.
Report condition and group effects for the artefacts de-
tailed for Item 3d (to test whether artefacts are more preva-
lent in certain participants and conditions).
Examples:
(i) ‘We observed an intra-subject effect of regulation condition
on HR [heart rate] (F(2,52) = 6.092; p = 0.004), which was
driven by an increased HR during the active (‘‘UP’’ and
‘‘DOWN’’) regulation conditions (Figure 6A). The relative
difference between ‘‘UP’’ and ‘‘DOWN’’ conditions was not
correlated with regulation capacity (2-tailed Pearson R =
0.038, p = 0.853, Figure 6C). For RVT [respiration
volume per time], there was a trend for an intra-subject
effect of regulation condition (F(2,52) = 3.148; p = 0.051,
Figure 6B). Additionally, we found a correlation between the
relative RVT-difference between the ‘‘UP’’ and ‘‘DOWN’’
conditions and regulation capacity (2-tailed Pearson R =
–0.450, p = 0.018, Figure 6D).’ (Marxen et al., 2016).
(ii) ‘In Fig. 6, mean heart and breathing rates obtained during
the different feedback conditions are plotted jointly for P02–
P05 and P09 (with all values being in the normal range).
While observed differences in heart rate across target-level
conditions were extremely weak, slightly augmented breath-
ing frequencies were detected for higher target-level condi-
tions on a descriptive level.’ (Sorger et al., 2018).
Feedback specifications
Item 4a. Report how the online feature extraction
was defined
This item is essential.
For example, a frequency band, frequency band ratio,
single region of interest, or functional connectivity measure.
Was it individualized or fixed across all participants? How
was it extracted (e.g. number and location of electrodes)?
Examples:
(i) ‘In each session, the IAF [individual alpha frequency] was
calculated as the peak frequency of the alpha band during
the first base rate and UA [upper alpha] was defined as the
frequency band from IAF to IAF +2 Hz.’ (Zoefel et al.,
2011).
(ii) ‘For the localizer scan, real-time statistical analyses were
carried out via an incremental general linear model (GLM)
using Turbo-BrainVoyager (TBV) . . . Target ROIs in the
respective groups were identified during a localizer scan
based on the t-statistic of the contrasts of interest, which
were defined as positive vs. neutral pictures in the NFE
group and scene vs. face pictures in the NFS group.
Target ROIs in the NFE group were limited to limbic and
frontal portions of the anterior cerebrum based on models of
emotion processing in the human brain [19].’ (Mehler et al.,
2018).
Item 4b. Report and justify the reinforcement
schedule
This item is essential.
For example, justify the reinforcement schedule, or the
feedback threshold criteria, in relation to existing neuro-
feedback literature and practice. Report how the feedback
was given (e.g. continuous or periodic, proportional or
binary). Report the amount of reward (e.g. percentage)
per subject and across subjects.
Example:
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‘Thus the patient actually controlled the quality of the picture
on the screen by his/her brainwaves: when the biofeedback par-
ameter was higher than threshold, the picture on the screen was
clear, otherwise the TV picture was blurred by the noise. The
threshold for the biofeedback parameter was defined by the
prefeedback baseline mean measure taken during a 2.5-min
feedback-free period with eyes opened at the beginning of the
first session in a way to grant that the biofeedback parameter
exceeds the threshold about 50% of the time.’ (Kropotov et al.,
2005).
Item 4c. Report the feedback modality and content
This item is essential.
Identify the feedback modality (e.g. visual, auditory, tact-
ile, proprioceptive), and the feedback format (e.g. video
clip, simple graphic, melody, tone).
Example:
‘Children from one group received the NFB treatment using as
reinforcement an auditory stimulus (Auditory Group, AG), and
children of the other group received a NFB treatment using as
reinforcement a visual stimulus (Visual Group, VG) . . . The
auditory stimulus was a tone of 500 Hz at 60 dB, and the
visual stimulus was a white square of 20 cm2 over a black
background of a computer monitor.’ (Ferna´ndez et al., 2016)
Item 4d. Collect and report all brain activity
variable(s) and/or contrasts used for feedback, as
displayed to experimental participants
This item is essential for points (ii) and (iii); and we en-
courage researchers to include points (i) and (iv–vi).
Time points may include: (i) a pre-training baseline;
(ii) rest blocks; (iii) training blocks; (iv) a post-training
baseline; (v) transfer run(s) without neurofeedback; and
(vi) long-term follow-up. Report the relevant units.
Example:
‘Thus the aim of this study was to focus on alpha neurofeed-
back and examine changes in three different measures: ampli-
tude, percent time, and integrated alpha, across four methods:
within sessions, across sessions, within sessions compared to
baseline, and across sessions compared to baseline.’ (Dempster
and Vernon, 2009).
Item 4e. Report the hardware and software used
This item is essential.
Include the versions.
Outcome measures (brain)
Item 5a. Report neurofeedback regulation success
based on the feedback signal
This item is essential.
Identify the baseline or contrast used (e.g. subject-specific
data from a previous session, reference data based on aver-
aged data from a normative group). Identify the compara-
tor run (e.g. training run or transfer run). Report both
statistically significant and non-statistically significant
findings.
Comment: We raise this point because some experiments
report only the changes in a subset of brain activity that
was not used for the neurofeedback signal.
Item 5b. Plot within-session and between-session
regulation blocks of feedback variable(s), as well as
pre-to-post resting baselines or contrasts
This item is essential.
Plotting the session course by comparing the session be-
ginning, middle, and end (for instance, by arbitrarily divid-
ing sessions into segments or using session blocks) allows
the assessment of within-session dynamics. Between-session
comparisons allow the assessment of the whole training
course on a temporally more abstract level.
Example:
‘Thus, relative to the VC group, the VTA feedback group
showed enhanced activation over the duration of the
ACTIVATE trial . . . Relative to baseline, the VTA Feedback
group increased activation in the first half of the trial (t(18) =
4.74, p 5 0.0005) . . . In addition to group differences, VTA
Feedback group activation at Post-test was significantly greater
than Pre-test (t(18) = 2.36, p 5 0.05) and greater than baseline
(early: t(18) = 2.88, p 5 0.05; late: t(18) = 3.29, p 5 0.005;
overall: t(18) = 3.52, p 5 0.005).’ Also, see Fig. 3 in MacInnes
et al. (2016).
Item 5c. Statistically compare the experimental
condition/group to the control condition(s)/group(s)
(not only each group to baseline measures)
This item is essential.
Comparing experimental and control groups/conditions
to their respective baselines, but not to each other fails to
test whether the experimental intervention outperforms the
control intervention(s) (Nieuwenhuis et al., 2011).
Example:
‘Figure 2 . . . Amygdalar hemodynamic response was assessed
using fMRI during exposure to (A) masked sad face presentations
(SN-NN condition) and (B) masked happy face presentations
(HN-NN condition). Error bars indicate 1 SEM.  indicates a
significant difference from the corresponding baseline at pcorrected
5 .05. # indicates a significant difference from the experimental
group at pcorrected 5 .05.’ (Young et al., 2017a).
Outcome measures (behaviour)
Item 6a. Include measures of clinical or behavioural
significance, defined a priori, and describe whether
they were reached
This item is essential.
For example, by using MCIDs to establish the magni-
tude of an effect to interpret as clinically meaningful (see
Engel et al., 2018; Lakens et al., 2018 for an overview on
establishing MCID values and smallest effect sizes of inter-
est). Many of these values remain open to discussion—
explain the reasoning behind the value used. Moreover,
collect data on acceptability, safety, and adverse effects.
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In this paper, we are using the term ‘behaviour’ in the
broad sense to encompass all non-physiological measures,
including self-reports.
Examples:
(i) ‘Minimal clinically important differences (MCIDs) were
defined as “the smallest differences in scores in the domain
of interest, which patients perceive as beneficial, and which
would mandate, in the absence of troublesome side effects
and excessive costs, a change in the patient’s management”
. . . The MCID value for the 10-m walk test was 0.19 m/s; 45
3.5 s for TUG; 46 and 5 points each for the UPDRS-Brad
and UPDRS-III.47 The MCID values of 5 points and 2 points
were adopted for BBS and PDQ-39 (mobility), respect-
ively.45,48’ (Costa-Ribeiro et al., 2017).
CRED-nf best practices checklist 2020 
Domain Item # Checklist item Reported on page # 
Pre-experiment 
 1a Pre-register experimental protocol and planned analyses 
1b Justify sample size 
Control groups 
 2a Employ control group(s) or control condition(s) 
2b When leveraging experimental designs where a double-blind is possible, use a 
double-blind 
2c Blind those who rate the outcomes, and when possible, the statisticians involved 
2d Examine to what extent participants and experimenters remain blinded 
2e In clinical efficacy studies, employ a standard-of-care intervention group as a 
benchmark for improvement 
Control measures 
 3a Collect data on psychosocial factors 
3b Report whether participants were provided with a strategy 
3c Report the strategies participants used 
3d Report methods used for online-data processing and artefact correction 
3e Report condition and group effects for artefacts 
Feedback specifications 
4a Report how the online-feature extraction was defined 
4b Report and justify the reinforcement schedule 
4c Report the feedback modality and content 
4d Collect and report all brain activity variable(s) and/or contrasts used for feedback, 
as displayed to experimental participants 
4e Report the hardware and software used 
Outcome measures 
Brain 5a Report neurofeedback regulation success based on the feedback signal 
 5b Plot within-session and between-session regulation blocks of feedback 
variable(s), as well as pre-to-post resting baselines or contrasts 
 5c Statistically compare the experimental condition/group to the control 
condition(s)/group(s) (not only each group to baseline measures) 
Behaviour 6a Include measures of clinical or behavioural significance, defined a priori, and 
describe whether they were reached 
 6b Run correlational analyses between regulation success and behavioural 
outcomes 
Data storage 
7a Upload all materials, analysis scripts, code, and raw data used for analyses, as 
well as final values, to an open access data repository, when feasible 
Figure 2 Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies
(CRED-nf) best practices checklist 2020. An online tool to complete this checklist is available at rtfin.org/CREDnf. Darker shaded boxes
represent ‘essential’ checklist items; lightly shaded boxes represent ‘encouraged’ checklist items. We recommend using this checklist in con-
junction with the standardized CRED-nf online tool (rtfin.org/CREDnf) and the CRED-nf article, which explains the motivation behind this
checklist and provides details regarding many of the checklist items.
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(ii) ‘The primary outcome measure was the arm section of the
Fugl–Meyer Assessment (FMA). A minimal clinically import-
ant difference (MCID) for this scale was set to 7 point.’
(Pichiorri et al., 2015).
Item 6b. Run correlational analyses between
regulation success and behavioural outcomes
This item is essential.
Examples:
(i) ‘For the mean alpha amplitude at P4 (the NFB controlled
parameter), we found no significant correlations with any
neglect severity measures (i.e. omissions on the left, center,
or right parts of the cancellation test, deviation on line bi-
section). However, as shown in Table 2, for the alpha vari-
ability and its left–right parietal asymmetry, we observed
significant correlations with performance on the cancellation
test.’ (Ros et al., 2017).
(ii) ‘The exploratory robust regression analysis suggested that
changes in self-efficacy predicted residualized depression
scores at the primary endpoint (R2 = 0.18, adjusted
R2 = 0.15, b = –0.187  0.073, Fig. 2c), such that increase
in self-efficacy was associated with less depression severity
(t30 = –2.551, p = 0.016).’ (Mehler et al., 2018).
Data storage
Item 7a. Upload all materials, analysis scripts, code,
and raw data used for analyses, as well as final values,
to an open access data repository, when feasible
This item is encouraged.
Description of consensus process
The authors T.R., S.E-G., and R.T.T. developed the idea for
a checklist of this type. They worked together, in the form of
an adversarial collaboration, to produce an initial outline of
the present checklist. They then requested input from re-
searchers involved in recent correspondences on neurofeed-
back, particularly those published in Brain and Lancet
Psychiatry. These researchers included K.D.Y., J.S.S.,
S.R.S., R.S., Mi.S., F.S., Ma.S, J-A.M-F., D.M.A.M., J.L.,
D.E.J.L., R.J.H., J.G., T.F., and M.A. T.R., S.E-G., and
R.T.T. then worked together to implement the comments
from the researcher listed above and produce a first complete
draft. This first complete draft was then sent to neurofeed-
back researchers involved in relevant discussions at recent
conferences [e.g. Society for Applied Neuroscience (SAN)
2016; real-time Functional Imaging and Neurofeedback
(rtFIN) 2017; Journe´e Nationale sur le Neurofeedback
2018], as well as the first-round contributors, to ask:
(i) whether they agreed with the contents of the checklist;
(ii) whether they would like to add, modify, or remove any
material; and (iii) to invite researchers they believe may be
interested in joining or commenting on the consensus.
Together, T.R., S.E-G., and R.T.T. discussed each of the
second-round comments and implemented those they
believed appropriate for this checklist. Not all comments
were addressed; in particular, specific comments relevant to
only a subset of neurofeedback research, as well as a few
points where contributors disagreed, were excluded from the
present checklist. This second draft was then shared with all
contributors before submitting for publication.
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